Thomas Arroll
Seattle Genetics, Inc.
Appearances
DateApril 30, 2020Speakers
DateApril 30, 2020The number and diversity of biotherapeutic modalities continues to increase. These represent complex modalities such as peptide and peptide conjugates, antisense oligonucleotides, DNA- and RNA-based therapies, drug conjugates, as well as viral vector-based therapeutics…Speakers
CBER, FDASeattle Genetics, Inc.CDER, FDAKite, a Gilead CompanyAstraZenecaNational Laborary for Drug Control, Morocco
